Merck KGaA Divests CDMO Unit to Lonza in Strategic US Manufacturing Pivot

DARMSTADT, Germany – November 03, 2026 – The era of the "do-it-all" life sciences conglomerate is quietly giving way to a new age of hyper-specialization. This strategic shift was thrown into sharp relief today as Merck KGaA, Darmstadt, Germany, announced a definitive agreement to divest its contract development and manufacturing organization (CDMO) business to Swiss manufacturing giant Lonza.

The transaction, valued at a mid-triple-digit million-euro amount—estimated by financial analysts to sit between €400 million and €600 million—marks a significant realignment in the pharmaceutical supply chain. Expected to close in mid-2027 subject to customary regulatory approvals, the deal will transfer a network of specialized United States manufacturing facilities to Lonza, alongside approximately 1,100 employees.

For corporate leaders watching the life sciences sector, this divestiture is more than a simple asset transfer. It is a masterclass in portfolio optimization, illustrating the difficult but necessary choices organizations must make when balancing capital-intensive operations against high-margin innovation.

The Margin Mandate: Why MilliporeSigma is Stepping Back

To understand the gravity of this divestment, one must look at the assets changing hands. The proposed transaction strips Merck KGaA of its CDMO operations associated with sites in Carlsbad, California; Madison and Verona, Wisconsin; bioconjugation operations in St. Louis, Missouri; and facilities in Indianapolis, Indiana. In the United States and Canada, the company’s Life Science business operates as MilliporeSigma.

Over the past few years, Merck KGaA had poured significant capital into these very facilities. In 2022, the company acquired Exelead for approximately $780 million to bolster its Indianapolis presence and announced a €59 million expansion of its high-potent active pharmaceutical ingredient (HPAPI) production in Verona. As recently as 2024, MilliporeSigma unveiled a $76 million expansion for antibody-drug conjugate (ADC) manufacturing in St. Louis.

Why abruptly shed these heavily funded assets? The answer lies in market volatility and the relentless pursuit of margin stability. The CDMO market, particularly post-COVID-19, has experienced severe cyclical pressures. In the first quarter of 2024, Merck KGaA’s CDMO sales dropped by 17% to €157 million, plagued by equipment destocking and unfavorable project phasing as biotech clients streamlined their own supply chains.

By divesting the capital-heavy manufacturing arm, the German science and technology firm is freeing up resources to double down on its highly profitable consumables, proprietary life science tools, and core technologies. It will also retain its lucrative BioReliance Contract Testing Services.

“Today’s announcement is another important step in advancing our mid- to long-term strategic agenda,” said Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany. “We continue to focus our portfolio on innovation-driven businesses that build on our core capabilities and strengthen our long-term competitive position within Life Science and across the entire portfolio.”

Jean-Charles Wirth, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Life Science, echoed this sentiment, framing the exit as a way to better serve clients. “A more concentrated Life Science portfolio will allow us to focus our investments on technologies and capabilities that build on our scientific leadership and make us an even stronger partner for our pharmaceutical, biotechnology and CDMO customers,” Wirth noted.

Lonza’s American Ambition: Doubling Down on Complex Modalities

If Merck KGaA is playing a game of margin optimization, Lonza is playing a game of geographic and technological scale. The Swiss CDMO, which already boasts a global workforce of roughly 17,000 employees, is aggressively expanding its footprint in the United States.

This acquisition will nearly double Lonza’s US CDMO footprint from four to nine sites, pushing its American workforce to over 6,000 employees. The strategic timing cannot be overstated. Amid evolving US biosecurity regulations and a bipartisan political push to onshore the production of critical medicines, pharmaceutical companies are increasingly demanding domestic manufacturing partners.

Furthermore, the specific capabilities of the acquired sites perfectly align with the biotech industry's pivot toward complex modalities. The facilities in St. Louis and Wisconsin are highly specialized in bioconjugation and ADCs—a rapidly growing class of targeted cancer therapies that require incredibly sophisticated, highly contained manufacturing environments.

“Our customers are looking for partners who combine deep scientific expertise with the capabilities and scale to support increasingly complex medicines from innovation through to commercial supply,” said Wolfgang Wienand, Chief Executive Officer of Lonza. “Integrating the CDMO business of Merck KGaA, Darmstadt, Germany, into Lonza will give our customers access to broader capabilities and additional manufacturing capacity in the US, a key market for Lonza. Most importantly, we are excited to welcome highly experienced new colleagues to One Lonza and, together with them, build an even stronger offering for our customers around the world.”

The Integration Challenge and Industry Ripple Effects

While the strategic rationales for both parties are sound, the execution will carry distinct challenges. Financial analysts at leading investment banks have broadly categorized the deal as a strategic positive for Lonza, allowing for higher utilization rates across a broader network. However, integrating five disparate sites and 1,100 new employees is a formidable operational hurdle.

Industry insiders note that the acquired facilities will initially operate with a CORE EBITDA margin below Lonza’s group average. Lonza’s leadership expects these sites to contribute approximately CHF 250 million in sales by 2028, but they project it will take until the mid-2030s for the new assets to reach peak profitability and match the broader group's margin levels. This long runway underscores the hidden pitfalls of massive scale-up acquisitions: the immediate drag on profitability while operational synergies are painfully ironed out.

For the broader CDMO sector, this deal accelerates an ongoing wave of consolidation. Lonza is already locked in fierce competition with giants like Thermo Fisher Scientific, Danaher, and WuXi Biologics. By removing Merck KGaA from the direct CDMO manufacturing chessboard and absorbing its capacity, Lonza is fortifying its defensive moat in North America.

A Blueprint for Future Biotech Supply Chains

From a leadership perspective, this transaction offers a compelling blueprint for organizational resilience. Merck KGaA demonstrated the rare corporate courage to reverse course on recent, massive capital investments when the underlying market dynamics shifted. Recognizing that they could generate superior shareholder value by supplying the "picks and shovels" of the biotech gold rush—consumables, bioreactors, and testing services—rather than operating the mines themselves, they made a decisive pivot.

Merck KGaA will continue to supply its broad portfolio of consumables and technologies to the very CDMO industry it is exiting, including Lonza. In doing so, it transitions from a competitor to an indispensable vendor.

Meanwhile, Lonza’s willingness to absorb short-term margin dilution for long-term strategic positioning in the US market highlights the premium placed on domestic biomanufacturing capabilities in a geopolitically fractured world. As supply chains continue to localize and therapies grow infinitely more complex, the companies that thrive will be those that choose a distinct lane—whether that is unparalleled manufacturing scale or elite technological innovation—and commit to it entirely.